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EGFR copy number per se can affect the clinical outcome of adenocar-
cinoma of the lung after surgical resection.
Methods: We analyzed 106 cases of primary pulmonary adenocarcino-
ma who underwent curative resection and whose parafﬁn blocks were 
available. We excluded patients who received preoperative chemother-
apy and who were presented with distant metastasis. The EGFR gene 
copy number was evaluated using ﬂuorescence in situ hybridization 
(FISH) and its prognostic implication was analyzed along with other 
clinical risk factors. 
Results: There were 43 males and 63 females and the mean age was 
59.4 (29-85) years. We detected a high EGFR gene copy number in 39 
cases (36.8%), among whom, 8 cases (7.5%) showed ampliﬁcation. 
The high EGFR gene copy was not associated with gender, smoking 
status, presence of bronchioloalveolar cell feature, or pathologic TNM 
stage. All patients were followed up at the clinic with mean follow 
up periods of 27.7 (2.9-69.6) months. The overall 5 year survival was 
54.6% and that of disease speciﬁc survival was 38.2%. The risk factors 
affecting the overall survival were male gender (p=0.0007), smoking 
history (p=0.0093), and advanced stage (≥IIA; p=0.0375) in univari-
able analysis. For disease speciﬁc survival, male gender (p=0.0333), 
absence of bronchioloalveolar feature (p=0.0223), advanced stage 
(p=0.0016), and ampliﬁcation of EGFR gene copy (p=0.0295) were 
risk factors in univariable analysis. In multivariable analysis, advanced 
stage (p=0.001) and EGFR gene ampliﬁcation (p=0.014) remained as 
signiﬁcant risk factors for poor disease speciﬁc survival.
Conclusions: We demonstrated that ampliﬁcation of the EGFR gene 
affected the clinical outcome of adenocarcinoma of the lung after surgi-
cal resection in terms of disease speciﬁc survival. This result provides 
an important message for the protocol design of future trials using 
EGFR inhibitor. As EGFR gene ampliﬁcation itself is a poor prognostic 
factor for disease recurrence, the EGFR gene copy number should be 
investigated and analyzed in the context of other clinical risk factors in 
such clinical trials. 
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Background: We evaluated the correspondence between EGFR 
mutations in NSCLC tissue and matched serum DNA and the value of 
EGFR mutations as a serological marker. 
Methods: 121 Spanish stage IV NSCLC p received customized ﬁrst- or 
second-line erlotinib monotherapy based on the presence of EGFR 
mutations in the tumor tissue. Serum genomic DNA was obtained from 
all p prior to erlotinib administration. EGFR exon 19 deletions were 
studied by length analysis of ﬂuorescently labeled PCR products and 
the exon 21 L858R mutation by a PCR Taqman assay. 
Results: The EGFR mutation status in the serum was consistent with 
that in the tumor tissue of 82/121 p (68%) and of 15/16 p (93.8%) with 
PS 2 had mutations. Overall, 64.3% of p had an exon 19 deletion and 
35.7% had L858R. 78% of mutations were found in females (P=0.01) 
and 77.6% in never-smokers (P=0.07). Response rate was 88% in 
p with mutations only in the tumor and 87% in p with mutations in 
tumor and serum. Complete responses were observed in 20% of p with 
mutations in tumor and serum vs 4% of p with mutations only in tumor 
(P=0.09). With a median follow-up of 6.8 months (m) (range, 1.2-17.6), 
time to progression (TTP) and median survival have not been reached. 
A trend to better outcome was seen in p without serum EGFR muta-
tions. TTP was longer for p with EGFR exon 19 deletions (not reached) 
than for p with L858R (7.7 m) (P=0.02). TTP for p with PS 2 with exon 
19 deletions was not reached, while it was 2.7 m for p with L858R 
(P=0.17). 
Conclusions: EGFR mutations in serum could be a non-invasive 
source of information on the genotype of the original tumor cells and 
could be a useful tool to predict p response to erlotinib, especially in p 
with poor PS.
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Background: The International Adjuvant Lung Cancer Trial (IALT) 
demonstrated an absolute survival rate beneﬁce of cisplatin based che-
motherapy of 4 % in surgically treated patients with non small cell lung 
carcinoma (NSCLC). To identify immunohistochemical biomarkers 
which correlate differently with survival in the chemotherapy and ob-
servation group (predictive analysis) we collected 867 parafﬁn blocks 
from 28 centers and made a histopathological review allowing selection 
of 783 tumors recorded as NSCLC with pathological parameters. These 
tumors came from 401 chemotherapy treated and 382 observation pa-
tients. Our aim was to evaluate the potential prognostic and predictive 
role of 3 non mitochondrial apoptotic factors, the death receptor Fas, 
its ligand FasL and survivin a G2-M cell cycle regulated protein with 
anti-apoptotic properties.
Methods: Immunohistochemical analysis was performed on 783 
parafﬁn sections with automated immunostainer Ventana using speciﬁc 
polyclonal antibodies Fas C20 and FasL N20 (Santa Cruz) and survivin 
R&D. Staining scores (0-300) were obtained by multiplication of the 
percentage of labeled cells by intensity of staining (1-3). The cut off 
score for discriminating positive from negative cases was 240 for Fas 
and FasL and 60 for survivin. 
Prognostic and predictive analysis was based on a Cox model adjusted 
on stage, type of surgery, histology, lymphoid inﬁltration, pathological 
N status, WHO performance status, age, sex, and center. Only p values 
below 0.01 were considered as signiﬁcant.
Results: Fas and FasL immunostaining were cytoplasmic and membra-
nous. Of 773 exploitable cases with positive internal controls (normal 
epithelial cells of a score 240-300) 73 % were Fas negative, 49 % FasL 
negative. Taking germinal cells as positive control 54 % of cases were 
survivin positive. 
Fas and FasL were positively correlated (distribution and intensity) 
with a Spearman’s correlation of 0.43 (p<0.0001). Survivin did not cor-
relate with Fas, FasL or P53.
In a logistic model with all variables, Fas positivity correlated with 
vascular invasion (p=0.006; lower in vascular invasion) and WHO 
status (p=0.008; higher in low WHO). FasL correlated with histology 
(p<0.0001; higher in adenocarcinoma) and pleural invasion (p=0.04). 
Survivin was lower in adenocarcinoma (p<0.0001), higher in males 
(p=0.0001) and lower in older patients (p=0.009). Fas, FasL, and sur-
vivin scores were not related to prognosis but the ratio of a Fas to FasL 
> or = 1 was related to longer survival (HR=0.72; p=0.02). 
None of these markers had predictive value for chemosensitivity at the 
level of signiﬁcance 0.01. However, a borderline signiﬁcant interaction 
was observed, chemotherapy being more efﬁcient for FasL negative 
(HR=0.69) as compared with FasL positive (HR=1.03; p=0.06), as 
well as for Fas:FasL ratio >1 (HR=0.51) as compared with a ratio of 1 
(HR=1.13) or a ratio <1 (HR=0.80; p=0.05).
Conclusion: Two non mitochondrial related apoptotic factors of the 
death receptor pathway have borderline predictive value (FasL and 
Fas/FasL). The beneﬁt of chemotherapy was observed among FasL 
negative patients and those with Fas:FasL ratio > 1. Current research 
is ongoing to pool these results with other adjuvant trial populations 
in order to validate their use in selecting patients for cisplatin-based 
chemotherapy. 
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Pemetrexed is a multi-targeted antifolate with clearly deﬁned meta-
bolic pathways as well as cellular targets that are responsible for its 
cytotoxicity speciﬁcally through polyglutamation. The accumulation 
of pemetrexed polyglutamates during steady state depends primarily 
on the activationinactivation processes by folylpolyglutamate synthe-
tase (FPGS) and gamma glutamyl hydrolase (GGH). The predominant 
mechanism of pemetrexed resistance has been shown to be due to im-
paired polyglutamation as a result of alterations in folylpolyglutamate 
synthetase (FPGS) activity. Additionally, increased expression of GGH 
has been associated with resistance to antifolates. Other mechanisms of 
resistance demonstrated in various preclinical models include changes 
in transport by the reduced folate carrier (SCL19A1). We hypothesized 
that polymorphisms in these genes may correlate with clinical response 
and/or toxicity (in particular neutropenia, mucositis and diarrhea) of 
pemetrexed. We used our resequencing data from 60 Caucasian DNA 
samples from the Coriell Cell Repository, to derive haplotype (ht) and 
LD-tag SNPs for FPGS namely 5’FR (-747), 5’FR (-573), rs10760502, 
IVS1 (28), IVS9 (48). We utilized the NCBI variation database and 
the HapMap database to obtain additional polymorphism information 
on GGH and SLC19A1. SNP genotype dataset based on the Caucasian 
population was loaded into Haploview. Polymorphisms with frequen-
cies greater than 5% were selected for aggressive 2- and 3-marker 
haplotype analysis at an r2 threshold of 0.8 and LOD threshold for 
multimarker test of 3.0. Haplotypes close to or above 2% were or-
ganized into single blocks for both GGH and SLC19A1 and ht-SNPs 
were derived. Tag-SNPs were also generated using the tagger software. 
The SNPs for GGH:rs12677953, rs11995525, rs7010484, rs3780130, 
rs13270305, rs11990678 and rs3780126 as well as those for SLC19A1:
rs1051298, rs3788189, rs2838956, rs2297291, rs2838958, rs914232, 
rs3788205 and rs1051266 were genotyped together with the FPGS 
SNPs from 61 patients who received pemetrexed on an NCCTG phase 
II NSCLC trial. The association between these tag SNPs and the thera-
peutic outcomes of the pemetrexed-treated patients will be presented. 
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Background: EGFR tyrosine kinase inhibitors are effective in a 
subset of NSCLC tumors. We previously showed that HDAC inhibi-
tion induces E-cadherin expression and sensitizes cells to EGFR TKI. 
